Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study

Fig. 3

Difference in 6mΔeGFR in mUA < 6.0 vs. ≥ 6.0 groups in various subgroups. ΔeGFR after 6 months (6mΔeGFR) were analyzed by dividing patients into mean serum uric acid (mUA) level < 6.0 mg/dl vs. mUA ≥ 6.0 mg/dl groups. The analyses were performed in various subgroups. a Men (n = 121) vs. Women (n = 57), b Age < 70 (n = 107) vs. age ≥ 70 years (n = 71), c systolic blood pressure (sBP) < 130 (n = 95) vs. sBP ≥ 130 mmHg (n = 83), d normal cholesterol levels (n = 84) vs. abnormal cholesterol levels (n = 94), e absence of diabetes mellitus (n = 133) vs. diabetes mellitus (n = 45). 6mΔeGFR represent the mean ± SE. *p < 0.05, **p < 0.01, compared with baseline UA level in each group (Wilcoxon signed-rank test). # p < 0.05, ## p < 0.01; comparison between mUA < 6.0 and mUA ≥ 6.0 mg/dl groups (Mann-Whitney U test)

Back to article page
\